Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Enzymatic Therapy
March 1, 2000
1 Min Read
Enzymatic Therapy
GREEN BAY, Wis.--Enzymatic Therapy, partnered with Immodal Pharmaka GmbH ofAustria, has created Saventaro, a cat's claw product scientifically proven andpatented for its positive effects on the natural and acquired immune systems.
Saventaro is the first Uncaria tomentosa product patented that has notetracyclic oxindole alkaloids (TOAs) and is standardized to contain 1.3 percentpentacyclic oxindole alkaloids (POAs). TOAs and POAs are compounds thatdistinguish the two specific chemotypes in Uncaria tomentosa. The two chemotypes,when present together, can inhibit the plant's beneficial effects on theacquired immune system.
Most cat's claw products do not disclose TOA content, and instead generalizethe label claim as containing oxindole alkaloids (OAs). This means that theconsumer may not receive a TOA-free product, which means there is no assurancethe product will offer any health benefits.
Saventaro is extracted solely from the cat's claw root, which contains 200percent more POA compounds than either the leaves or stem hold. For additionalinformation, call (920) 469-4419.
You May Also Like